A5024058623- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Cancer survivorship and care
- Biosimilars and Bioanalytical Methods
- Breast Cancer Treatment Studies
- T-cell and B-cell Immunology
- Chronic Lymphocytic Leukemia Research
- vaccines and immunoinformatics approaches
- Advanced Breast Cancer Therapies
- Viral-associated cancers and disorders
- Multiple Myeloma Research and Treatments
- Economic and Financial Impacts of Cancer
- Monoclonal and Polyclonal Antibodies Research
- Estrogen and related hormone effects
- Pharmacogenetics and Drug Metabolism
- Lymphoma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Blood disorders and treatments
- Inflammatory mediators and NSAID effects
- Neutropenia and Cancer Infections
- Cancer Genomics and Diagnostics
Breast Center
2012-2024
University Hospital of Zurich
1998-2024
University of Zurich
2002-2024
Brustzentrum Klinik St. Anna
2023-2024
See-Spital
2023
Hirslanden Klinik Im Park
2007-2022
University of Cartagena
2020
Immunologie-Zentrum Zürich
2014-2019
Onkozentrum Dresden
2012
Herzgefäss Medizin Klinik Im Park
2012
Background We previously demonstrated the successful tissue engineering and implantation of functioning autologous heart valves based on vascular-derived cells. Human marrow stromal cells (MSC) exhibit potential to differentiate into multiple cell-lineages can be easily obtained clinically. The feasibility creating engineered (TEHV) from MSC as an alternative cell source, impact a biomimetic in vitro environment differentiation was investigated. Methods Results were isolated, expanded...
Background: The well-being of breast cancer patients and reporting adverse events require close monitoring. Mobile apps allow continuous recording disease- medication-related symptoms in undergoing chemotherapy. Objective: aim the study was to evaluate effects a mobile app on patient-reported daily functional activity supervised unsupervised setting. Methods: We conducted randomized controlled 139 Patient status self-measured using Eastern Cooperative Oncology Group scoring Common...
Mantle cell lymphoma accounts for 6% of all B-cell lymphomas and is generally incurable. It characterized by the translocation t(11;14) leading to cyclin D1 over-expression. Cyclin downstream mammalian target rapamycin threonine kinase can be effectively blocked inhibitors. We set out examine single agent activity orally available inhibitor everolimus in a prospective, multicenter trial patients with relapsed or refractory mantle (NCT00516412).Eligible who had received maximum three prior...
Aim Several multigene expression-based tests offering prognostic and predictive information in hormone-receptor positive early breast cancer were established during the last years. These provide on distant recurrences can serve as an aid therapy decisions. We analyzed recently validated reverse-transcription-quantitative-real-time PCR-based multigene-expression Endopredict (EP)-test 34 breast-cancer cases compared EP scores with Oncotype DX Recurrence-scores (RS) obtained from same samples....
The majority of patients with multiple myeloma (MM) have persistence minimal residual disease (MRD), as determined by polymerase chain reaction (PCR) detection clonal immunoglobulin H (IgH) gene rearrangements. As a result, PCR analysis has not provided clinically useful prognostic information in patients. Instead, quantitative approaches are required to predict patient outcomes and assess response novel treatment strategies. We adapted real-time technology quantify cells using the IgH...
Adding bevacizumab to chemotherapy improves response rates and progression-free survival (PFS) in metastatic breast cancer (mBC). We aimed demonstrate decreased toxicity with metronomic chemotherapy/bevacizumab compared paclitaxel/bevacizumab. This multicenter, randomized phase III trial either paclitaxel (arm A) or daily oral capecitabine-cyclophosphamide B) as first-line treatment patients HER2-negative advanced cancer. The primary endpoint was the incidence of selected grade 3–5 adverse...
<b><i>Background: </i></b>Melatonin is an endocrine hormone secreted by the pineal gland during night hours that provides several biological functions in circadian rhythm of humans. Due to anti-estrogenic properties, melatonin considered exhibit a protective role against development breast cancer (BC). Moreover, disruption production through environmental influences, such as work, assumed be risk factor for BC. <b><i>Materials and Methods:...
Abstract Breast cancer is a biologically diverse disease with treatment modalities selected based on tumor stage and biology. Distinct intrinsic subtypes surrogate biomarker profiles play major role for therapeutic decisions. Response rates to systemic local treatments as well the interaction epidemiological risk factors have been validated in clinical trials translational studies. This retrospective study addresses question how neoadjuvant chemotherapy setting changed during past 15 years...
The WSG-PRIMe Study prospectively evaluated the impact of 70-gene signature MammaPrint® (MP) and 80-gene molecular subtyping assay BluePrint® on clinical therapy decisions in luminal early breast cancer.452 hormone receptor (HR)-positive HER2-negative patients were recruited (N0, N1). Physicians provided initial recommendations based clinicopathological factors. After prospective risk classification by MammaPrint/BluePrint was revealed, post-test treatment actual recorded. Decisional...
Kaposi's sarcoma-associated herpesvirus (KSHV) specific T cell responses and KSHV viremia were analyzed in seven HIV-infected patients with active sarcoma lesions who initiated highly antiretroviral therapy, compared between improved those progressive requiring further systemic chemotherapy. Patients controlled disease demonstrated undetectable together KSHV-specific CD8+ cells secreting interferon-γ tumor necrosis factor-α, whereas progressors showed increasing weak or no T-cell responses....
Clinical practice adherence to current guidelines that recommend primary prophylaxis (PP) with granulocyte colony-stimulating factors (G-CSFs) for patients at high (≥20 %) overall risk of febrile neutropenia (FN) was evaluated.Adult breast cancer, non-small cell lung cancer (NSCLC), small-cell (SCLC), or ovarian were enrolled if myelotoxic chemotherapy planned, and they had an investigator-assessed FN ≥20 %. The outcome incidence.In total, 1,347 analysed (breast n = 829; NSCLC, 224; SCLC,...
Digital patient monitoring gains importance for quality of clinical cancer care. Our case report provides insight into usability and acceptance a smartphone app electronically captured patient-reported outcomes in patients undergoing immunotherapy. During 3 months, 6 with advanced or metastatic PD-L1-positive the lung, prostate, bladder who underwent checkpoint immunotherapy were using Consilium standardized structured electronic reporting symptoms therapy side effects. We evaluated number...